ACKNOWLEDGEMENT: Cooperation on data collection: All Showa University in Rheumatoid Arthritis (ASHURA) group


This work was supported by JPUS KAKENHI Grant Number JP17K09324, Kenji Sanada: None declared, Yuko Mitamura: None declared


AB0341 REASONS FOR DROP-OUT IN RHEUMATOLOGY SPECIALTY CARE OF ELDERLY RHEUMATOID ARTHRITIS PATIENTS

Shinichi Mizuki, Matsuyama Red Cross Hospital, The Center for Rheumatic Diseases, Matsuyama, Japan

Background: The difference between total and healthy life expectancies were 12.3 and 8.8 years for women and men respectively in 2016, in Japan. Rheumatoid arthritis (RA) not only reduces daily living activities due to joint symptoms but also deteriorates the life prognosis due to systemic inflammation. That is, patients with RA are short for both total and healthy life expectancy. In recent years, the need for rheumatologist to provide specialty medical care to elderly patients with RA has been expanding. However, some elderly patients drop out of specialty treatment and care. To date, there is little information concerning background of patients who drop out.

Objectives: To investigate reasons and characteristics of elderly RA patients who drop out from rheumatology specialty medical care.

Methods: Of RA patients who had been visited our rheumatology specialty facility in 2016, we defined as drop-out when the patients did not return to the hospital in 2017. We surveyed age, gender, disease activity, and reason for drop-out retrospectively from medical records and questionnaires.

Results: Of 2,092 patients with RA who visited to our department, 156 patients (7.5%, 95% confidential interval: 6.4 – 8.6%) dropped out. Among drop-out patients, 101 patients were older than 65. 37 patients (37%) dropped out due to comorbidities including death (group C), 32 (32%) patients were introduced certified rheumatologists near the patients residences (group R). Twenty-two patients were due to unknown reasons, nine were due to remission, and one patient moved out to other area. Average age of both group C and R were eighty years old. Glucocorticoid user rate (C: 89%, R: 71%) and dose (C: 5.6 mg, R: 5.7 mg) were similar in the two groups. Patients in group C showed less use of methotrexate (C: 19% vs R: 58%, P < 0.01) compared with group R patients. Simple disease activity index was similar, however, higher modified health assessment questionnaire was observed in group C patients (C: 1.13 vs R: 0.25, P<0.01).

Conclusion: Some elderly RA patients, especially may drop out from rheumatology specialty care due to comorbidities. Regional co-management should be constructed so that elderly patients could continue receiving RA specialized care.

Disclosure of Interests: None declared


AB0342 DEPRESSION ON PATIENTS WITH RHEUMATOID ARTHRITIS

Simeon Monov1, 2, Russka Shumalova1, Elena Miloshova1, Daniela Monova2
1Medical University – Sofia, Department of Rheumatology, Sofia, Bulgaria; 2Medical University – Sofia, Department of Rheumatology, Sofia, Bulgaria

Background: Rheumatoid arthritis (RA) is a chronic representative inflammatory autoimmune disease. The association of disease activity and pro-inflammatory cytokines with depression has not been sufficiently investigated.

Objectives: The aim of this study is to analyze the association between disease activity and depression using Patient Help Questionnaire (PHQ-9) in patients with rheumatoid arthritis (RA). We also examined the outcome of intervention on depression score and the prevalence of depression and risk factors for depression and deterioration of depressive symptoms in RA patients.

Methods: 146 RA patients with a mean age of 51±11.2 years were included in the study. Demographic and laboratory data were examined. Disease activity score 28-joint count C-reactive protein (DAS 28-CRP) was performed to assess disease activity of RA. PHQ-9 scores were collected at each clinic visit. Physicians assessed corresponding disease activity using Clinical Disease Activity Index (CDAI). Patients with at least moderate depression (PHQ-9 > 10) were offered depression intervention, counseling or medications. PHQ-9 was re-administered after intervention.

Results: 119 of RA patients were females, the average disease duration was 6.8 ± 5.9 years. Depression was diagnosed in 38 of RA patients: 18 - mild, 13 - moderate and 7 - moderately severe. Severity of depression positively correlated with disease activity in RA patients (p <0.05). RA patients with moderate/high CDAI had significantly higher PHQ-9 than those with low CDAI (p <0.001). Of 7 patients who met criteria for depression intervention, 6 were treated and 1 - declined. With treatment 5 patients had improved PHQ-9 scores, 1 patient worsened, and 1 patient had no change in score. The risk of developing a depressive disorder is highest between 5 and 10 years of onset of the disease and depression is a better predictor of work disability than disease activity and response to treatment. Depression is associated with more pain, fatigue and impaired quality of life. Therefore, the risk to develop a depression is increased with impaired function as measured by the health assessment questionnaire (HAQ). Increased disease activity increases the risk for depression in RA. The severity of disease activity of RA, DAS 28-CRP (p=0.001, r=1.75, 95% CI 1.08-2.64) and severity of fatigue (OR 1.32 95%, CI 1.12-1.27) were associated with depression and deterioration of depressive symptoms in the multivariate analysis. Among the components of DAS 28-CRP, patient assessment for global health and abilities for daily performance were more related to depression. Depression unfavorably influences the response to therapy, the rate of remission is lower and the mortality is increased in RA patients. Taken together, this indicates that it is necessary to detect a depression in patients with RA as early as possible in order to initiate appropriate treatment of depression in such cases.

Conclusion: Our study shows depression in 19.18% of patients. Correlation between disease activity and depression score is found in RA patients. Depression intervention resulted in PHQ-9 improvement in some patients, supporting the benefit of depression screening and treatment in rheumatology practice. Depression was related with the level of fatigue and high RA disease activity, which was associated with impaired ability to perform activities of daily life. Strict control of fatigue and disease activity to improve one’s capacity to perform daily life activities would be important to regulate depression. Depression is common and associated with worse outcomes among patients with RA.

Disclosure of Interests: None declared


AB0343 ANTIRHEUMATIC THERAPY IS NOT ASSOCIATED WITH CHANGES IN CIRCULATING N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE (NT-proBNP) LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS

Thao Nguyen1, Gia Deyab2, Morten Fagerland2, Stefan Ageewall2, Gro Ei lseth2, Mark Feinberg3, Knut Mikkelsen4, Øystein Forre5, Ivana Hollan6,7,1, Liellehammer Hospital for Rheumatic Disease, Lillehammer, Norway; 2Innlandet Hospital Trust, Department of Medical Biochemistry, Lillehammer, Norway; 3Oslo University Hospital, Oslo Centre for Biostatistics and Epidemiology, Oslo, Norway; 4Oslo University Hospital, Ullevål, Department of Cardiology, Oslo, Norway; 5The Artic University of Norway, Department of Rheumatology, Tromsø, Norway; 6Harvard Medical School, Boston, United States of America; 7Brigham and Women's Hospital, Department of Cardiology, Boston, United States of America; 8University of Oslo, Oslo, Norway

Background: Patients with rheumatoid arthritis (RA) are predisposed to impaired cardiac function and heart failure (HF). While the pathophysiology has not been fully elucidated yet, inflammation is suspected to play an important role. However, the impact of disease-modifying antirheumatic drugs on cardiac dysfunction in RA remains controversial. Although anti-inflammatory drugs might have protective effects, some of them, i.e. tumour necrosis factor inhibitors (anti-TNF), might also negatively influence cardiac function. Serum NT-proBNP (s-NT-proBNP) is used as a biomarker of cardiac function, and levels ≤125 ng/L with high probability exclude HF.

Objectives: To examine effects of methotrexate (MTX) and anti-TNF regimens on s-NT-proBNP in patients with active RA, and to assess associations between s-NT-proBNP and endothelial function (EndoF).

**Methods:** From the observational PSARA study, we examined 64 RA patients starting with MTX monotherapy (n=34) or anti-TNF with MTX co-medication (n=30) due to active disease. All patients starting with anti-TNF regimens had been previously unsuccessfully treated with MTX. s-NT-proBNP (ELISA), EndoF (measured by finger plethysmography), and other laboratory and clinical parameters were evaluated at baseline and after 6 weeks and 6 months of treatment.

**Results:** Median age was 57 years (range 28-79), and 73% were women. 17 (27%) patients had CVD (history of angina, MI, heart surgery, PTA, cerebrovascular disease, thromboembolism, aortic aneurysm, peripheral artery disease). None of the patients had known/symptomatic HF. There were no statistically significant differences between s-NT-proBNP levels at baseline (median 2241 ng/L [IQR 9002]) and after 6 weeks (median 2300 ng/L, [IQR 8960]) and 6 months (median 2358 ng/L [IQR 7772]) of anti-TNF treatment (p=0.992 and p=0.528, respectively). There were no significant differences in the effects of MTX monotherapy and anti-TNF regimens on s-NT-proBNP levels (p=0.779; p=0.421).

At baseline, 57 (89%) patients had s-NT-proBNP>125 ng/L, and 44 (69%) had high s-NT-proBNP levels (s-NT-proBNP>450 ng/L in patients <50 years old and >900 ng/L in patients >50 years old), and these frequencies did not significantly change with anti-TNF treatment. s-NT-proBNP was not related to EndoF.

**Conclusion:** A large proportion of RA patients without known HF had elevated s-NT-proBNP levels, which might indicate subclinical impairment of cardiac function. s-NT-proBNP levels were not influenced by six-month MTX and/or anti-TNF treatment. Thus, in contrast to some previous studies, our data does not support the notion that anti-inflammatory treatment protects against HF, and that anti-TNF treatment has negative effect on cardiac function in RA. Nevertheless, definitive conclusions cannot be drawn by our study, e.g. due to limitations of s-NT-proBNP as surrogate marker of HF. Cardiac function in terms of s-NT-proBNP levels was not related to EndoF.

**REFERENCES**


**Disclosure of Interests:** None declared


---

**SINGLE CENTER RETROSPECTIVE REAL WORLD DATA ANALYSIS**

**AB0344**

**Comparative analysis of side effects between patients treated with and without corticosteroid at DMARDS-starting point.**

**Michihiro Ogasawara1**, Yusuke Shimada2, Yoshuikyo Abe1, Ken Yamaji3, Satoshi Hori4, Naoto Tamura5, 1Juntendo University Faculty of Medicine, Department of Internal Medicine and Rheumatology, Tokyo, Japan; 2SECOM Co., Ltd., Intelligent Systems Laboratory, Tokyo, Japan; 3Juntendo University Graduate School, Medical Informatics Department, Tokyo, Japan

**Background:** In the EULAR recommendation on rheumatoid arthritis (RA) treatment, short-term steroid combination should be considered at the start of DMARDs treatment. In this study, we analyzed the present condition of steroid combined use in Japan and the actual situation of side effects in recent years. **Objectives:** RA patients who started treatment with DMARDs at our hospital from July 2008 to April 2018. **Methods:** A new incidence of hypertension (HTN), diabetes (DiB), dyslipidemia (HLP), infection (INF), HTN vs.65 and under 65 years old (p=0.00583, p=0.022), sex (66.3% for man vs 23.8% for woman, p<0.001). Then, a logistic regression was classified 85.3% of cases. The Wald statistics showed that at least 6 restriction fragment length polymorphism (TNFA C-863A, rs1800629, TNFA C-863A (rs1800830), TNFA C-2578A (rs699947), MMP9 C-1562T (rs3025059), MMP9 -1562T (rs3918243) and polyinosine chain reaction (IL1B T-31C (rs1143627), IL4 C-590T (rs2243250), IL10 C-592A (rs1800872), IL10 A-1082G (rs1800896), VEGFA C-936T (rs2530593), MMP2 C-1306T (rs2438650)). Descriptive statistics, Chi-squared test, logistic regression with Wald statistics were used for data analysis. Results are presented as median and 25th/75th percentiles (Me 25th percentile; 75th percentile).

**Results:** Atherosclerotic plaques (API) were found in 59 (27.8%) patients. API revealed were strongly associated with age (66.0 yrs [59.0; 73.0]) with API vs 55.0 yrs [42.0; 61.0] without API, p<0.001 and sex (51.6% for man vs 23.8% for woman, p<0.001). Then, a logistic regression was performed to determine which variables analyzed are predictors of a carotid atherosclerotic lesion. Regression results had demonstrated that the model was statistically reliable in distinguishing between patients with API and without [2 Log Likelihood = 146.53, p<0.001]. The model correctly classified 85.3% of cases. The Wald statistics showed that at least 6 parameters were principal — age (B=3.114, p<0.001), hypertension (B=3.114, p<0.001), smoke (B=2.167, p<0.001), positive rheumatoid factor (B=1.674, p=0.038), body mass index (B=1.559, p<0.001) and recessive restriction fragment length polymorphism (TNFA C-863A (rs1800629), TNFA C-2578A (rs699947), MMP9 C-1562T (rs3025059), MMP9 -1562T (rs3918243) and polyinosine chain reaction (IL1B T-31C (rs1143627), IL4 C-590T (rs2243250), IL10 C-592A (rs1800872), IL10 A-1082G (rs1800896), VEGFA C-936T (rs2530593), MMP2 C-1306T (rs2438650)). Descriptive statistics, Chi-squared test, logistic regression with Wald statistics were used for data analysis. Results are presented as median and 25th/75th percentiles (Me 25th percentile; 75th percentile).

**Conclusion:** Age, hypertension, smoke, positive rheumatoid factor, low body mass index and recessive allele in TNFA C-863A (B=1.338, p<0.005) using parameters obtained the ROC-curve was constructed. Area under ROC curve were 0.900 (SE 0.022; 95%CI 0.857-0.942, P<0.001). Sensitivity and specificity calculated by Youden’s Index were 79.7% and 87.5%, respectively.

**References:** Age, hypertension, smoke, positive rheumatoid factor, low body mass index and recessive allele in TNFA C-863A were associated with carotid atherosclerosis.

**References**


**Disclosure of Interests:** None declared